Mochi Health Dosage Chart: Units Guide

Mochi partners with Aequita Pharmacy for its compounded GLP-1 medications. Like most 503A compounding pharmacies serving the telehealth weight loss market, Aequita standardizes on a small set of concentrations to keep prescription workflows clean and to make the syringe math survivable for patients dosing at home.

Compounded semaglutide from Mochi: typically 2.5 mg/mL.

The standard 5 mg vial is reconstituted to 2 mL of bacteriostatic water, producing 2.5 mg/mL. Some compounding runs ship at higher concentration (5 mg/mL) for higher-dose patients. Always check the label.

Compounded tirzepatide from Mochi: typically 10 mg/mL.

The standard 30 mg vial is reconstituted to 3 mL of bacteriostatic water, producing 10 mg/mL. Higher-dose vials sometimes ship at 12 mg/mL or 15 mg/mL.

The concentration matters because your insulin syringe reads in units, where 100 units equals 1 mL. The unit number you draw is determined by two things: the dose your provider prescribed (in mg) and the concentration of your specific vial (in mg/mL). Change either one and the unit number changes.

The single math equation that drives every chart in this article:

Units = (Dose in mg / Concentration in mg/mL) x 100

At 2.5 mg/mL semaglutide, 0.25 mg = (0.25 / 2.5) x 100 = 10 units. At 10 mg/mL tirzepatide, 2.5 mg = (2.5 / 10) x 100 = 25 units. Memorize the equation, not the chart.

For step-by-step reconstitution and unit math, see our reconstitution calculator and our semaglutide dosage chart for the full clinical reference. For the broader Mochi service review, see Mochi Health reviews.

Mochi follows the FDA-approved Wegovy titration ladder for compounded semaglutide. The ladder exists because semaglutide's gastrointestinal side effects (nausea, vomiting, constipation) are dose-dependent and escalate with abrupt dose changes. The 4-week intervals give your gut time to adapt before the next step.

Standard 17-week titration on Mochi compounded semaglutide at 2.5 mg/mL:

Same chart at 5 mg/mL semaglutide (less common Mochi formulation):

Note that the milligram dose is the same in either chart. Only the unit number changes because the concentration changed. This is the most common source of dosing errors in compounded GLP-1 use: a patient on 2.5 mg/mL gets a vial refill at 5 mg/mL and continues to draw the old unit number, doubling their actual dose.

Wilding et al., 2021 STEP-1 trial showed mean weight reductions of 14.9% over 68 weeks at the 2.4 mg weekly maintenance dose. The titration ladder Mochi follows is the same one used in STEP-1.

For the standalone semaglutide titration walkthrough, see semaglutide titration schedule and our semaglutide dosage chart. Use the semaglutide dosage calculator for any non-standard concentration.

Mochi follows the Mounjaro/Zepbound titration ladder for compounded tirzepatide. Tirzepatide has six dose steps (vs five for semaglutide) and a slightly more permissive gastrointestinal profile, but the same 4-week interval rule applies.

Standard 25-week titration on Mochi compounded tirzepatide at 10 mg/mL:

At 100 to 150 units, you exceed the capacity of a single 1 mL insulin syringe. Mochi typically ships 1 mL syringes; for doses above 100 units you either split into two injections at the same site (back-to-back) or request 1.5 mL or 3 mL syringes. Most Mochi providers will switch you to a higher-concentration vial (12 mg/mL or 15 mg/mL) at this stage to keep the volume manageable.

Same chart at 12 mg/mL tirzepatide:

Same chart at 15 mg/mL tirzepatide:

Jastreboff et al., 2022 SURMOUNT-1 trial showed mean weight reductions of 15.0%, 19.5%, and 20.9% at the 5, 10, and 15 mg doses over 72 weeks. The pharmacokinetic basis for the once-weekly dosing comes from Bastin and Andreadis, 2022, which characterized tirzepatide's ~5 day half-life that supports the weekly schedule.

For the standalone tirzepatide titration walkthrough, see our tirzepatide titration schedule and compound tirzepatide dosage chart. Use the tirzepatide dosage calculator for any non-standard concentration. For switching between providers, see semaglutide to tirzepatide conversion.

Mochi runs all titration through the patient portal and, when needed, a follow-up video visit. The default escalation rule is the standard 4-week interval, but providers adjust based on how you tolerate the current dose.

The Mochi titration decision tree (general pattern, individual cases vary):

1. 1.You have been on the current dose for at least 4 weeks. This is the floor. Faster titration increases gastrointestinal side effects without speeding weight loss meaningfully.

1. 1.Your weight loss trajectory is within the expected range. For semaglutide, this is roughly 1 to 2% body weight per month at lower doses, ramping to 2 to 4% per month at maintenance. For tirzepatide, it is similar but typically faster after the 5 mg dose.

1. 1.Side effects are tolerable. Mild nausea that fades within 48 hours of injection is normal. Persistent vomiting, severe constipation, or symptoms that interfere with daily life are reasons to hold the current dose, not escalate.

1. 1.You have not had any new contraindications or red-flag symptoms. Acute pancreatitis symptoms (severe abdominal pain radiating to the back), gallbladder symptoms, or significant changes in mood require medical review before escalation.

If you meet all four criteria, your provider approves the next step in the ladder. If you do not, you stay on the current dose for another 4 weeks.

Mochi specifically allows holding at sub-maximal doses indefinitely. If 1 mg semaglutide or 7.5 mg tirzepatide produces good weight loss with tolerable side effects, you can stay there. There is no clinical mandate to climb to the maximum. The SURMOUNT-1 data suggests diminishing returns above 10 mg tirzepatide for many patients, and many Mochi patients maintain at 7.5 to 10 mg long-term.

For more on the maintenance phase, see tirzepatide long-term side effects and semaglutide weight loss expectations. For the broader Mochi care model, see Mochi Health reviews.

Every Mochi vial that arrives from Aequita Pharmacy carries a label with the same essential information. Reading it correctly is the difference between a 0.25 mg dose and a 2.5 mg dose.

What the label tells you:

• Drug name: "Semaglutide" or "Tirzepatide" (sometimes "Semaglutide/Cyanocobalamin" if B12 is included)
• Concentration: "2.5 mg/mL" or "10 mg/mL" (this is the number that drives every unit calculation)
• Total volume: "2 mL" or "3 mL" (concentration x volume = total mg in vial)
• Lot number and expiration date
• The compounding pharmacy name (Aequita)
• The prescribing provider name and your patient name

The four-step draw routine:

1. 1.Confirm the concentration on the label. Read it out loud. If it changed from your last vial, recalculate your unit number using the formula in this article (units = mg / mg/mL x 100). Do not assume the unit number is the same as before.

1. 1.Wipe the rubber stopper with an alcohol swab. Wait 10 seconds for the alcohol to dry. Wet alcohol can interfere with the stopper seal.

1. 1.Pull air into your insulin syringe equal to your dose volume. If you are drawing 25 units, pull 25 units of air. Insert the needle into the inverted vial and inject the air. This equalizes pressure and makes the draw clean.

1. 1.Pull your dose to the exact unit mark. Hold the syringe vertical, tap any air bubbles to the top, push the bubbles out and re-pull to the correct unit. Withdraw the needle.

The injection itself: subcutaneous, abdomen or thigh, 90-degree angle for 5/16 inch needles, 45-degree angle for 1/2 inch needles. Rotate sites between injections to prevent lipohypertrophy. For step-by-step injection technique, see how to inject peptides and how to inject semaglutide.

For storage between doses, refrigerate at 36 to 46 degrees Fahrenheit. Do not freeze. Do not leave at room temperature for more than 24 hours total over the vial's life. See how to store peptides and how long do reconstituted peptides last.

Mistake 1: Treating units and milligrams as interchangeable. A patient prescribed 2.5 mg tirzepatide reads "2.5" on the syringe and draws 2.5 units. At 10 mg/mL concentration, 2.5 units = 0.25 mg. The patient is dosing at one-tenth the prescribed dose for weeks before noticing zero weight loss. The fix: always do the math (units = mg / mg/mL x 100). For 2.5 mg at 10 mg/mL, that is 25 units, not 2.5.

Mistake 2: Drawing from a new concentration without recalculating. Mochi sometimes ships a higher-concentration vial as your dose climbs. A patient on 0.5 mg semaglutide at 2.5 mg/mL was drawing 20 units. The new vial arrives at 5 mg/mL. The patient draws 20 units out of habit. Actual dose: 1.0 mg. Double the prescribed amount, double the side effects. The fix: every new vial, redo the math.

Mistake 3: Climbing the ladder without finishing the 4-week interval. A patient at 0.25 mg semaglutide for 2 weeks decides they "feel fine" and jumps to 1 mg. The expected gastrointestinal response is severe nausea and vomiting that derails them for a week. The fix: hold each dose for a full 4 weeks regardless of how easy the current dose feels. Side effects on a step-up emerge in week 2 to 3 of the new dose.

Mistake 4: Switching from compounded to brand-name without continuity coordination. A Mochi patient at 10 mg compounded tirzepatide gets insurance coverage for Zepbound and switches. They start Zepbound at the 2.5 mg pen because "that's the starting dose." This is wrong. You continue at the same milligram dose; you do not restart titration. The fix: tell your prescriber you are switching and have them write the prescription at your current dose level. See tirzepatide cost with insurance for switching logistics.

Mistake 5: Drawing from an expired or improperly stored vial. Compounded semaglutide and tirzepatide are stable for ~28 to 56 days refrigerated after reconstitution, depending on the formulation. After that, peptide degradation accelerates. The vial may look identical but contain less active drug. Result: stalled weight loss attributed to "drug failure." The fix: write the date of first use on the vial label and respect the beyond-use date the pharmacy listed.

Mistake 6: Stacking compounded vials with brand pens during a transition. Some patients keep both running "to be safe." This produces double dosing and severe side effects. The fix: choose one pathway and stop the other. Coordinate with your provider during any switch.

Mistake 7: Injecting into a recently bruised or hardened site. Lipohypertrophy from repeated injection at one site reduces absorption by 20 to 40%. The patient interprets this as drug failure and requests a dose increase that they do not actually need. The fix: rotate sites systematically. Abdomen left, abdomen right, left thigh, right thigh, repeat.

For broader injection error prevention, see our peptide safety guide, tirzepatide drug interactions, and semaglutide side effects.

Most telehealth compounded GLP-1 providers use the same basic concentrations because they all source from a small set of 503A compounding pharmacies and follow the same FDA-approved titration ladders. The differences are at the margins.

Mochi vs Henry Meds: Henry Meds typically ships compounded semaglutide at 2.5 mg/mL and tirzepatide at 10 mg/mL, similar to Mochi. The titration ladder is identical. Pricing differs (Henry runs roughly $300/month flat for tirzepatide; Mochi runs $199/month plus $79 membership). See Henry Meds reviews for the full breakdown.

Mochi vs Ivim Health: Ivim Health uses similar concentrations but has occasionally shipped tirzepatide at 5 mg/mL for early-titration patients, doubling the unit count for the same milligram dose. Always check the label. Ivim's titration logic is more conservative on the upper end (often holding at 10 mg longer before climbing to 12.5 or 15). See Ivim Health reviews.

Mochi vs Brand-name Wegovy or Zepbound pens: Brand pens deliver fixed milligram doses per click. There is no unit math. Wegovy pens come at 0.25, 0.5, 1, 1.7, and 2.4 mg pre-set doses. Zepbound pens come at 2.5, 5, 7.5, 10, 12.5, and 15 mg pre-set doses. The titration intervals are the same as compounded products because they follow the same clinical evidence base (Wilding et al., 2021; Jastreboff et al., 2022).

Mochi vs research-vendor semaglutide or tirzepatide: Research vendors like Polaris Peptides, Transcend Peptides, or Amino USA ship in higher concentrations (often 5 mg/mL semaglutide, 20 mg/mL tirzepatide) because the vials are sized for "research" use. The unit math gets correspondingly smaller. There is no clinical oversight, no prescriber, and no titration framework, which puts the dosing burden entirely on the buyer.

The headline summary: as long as you read your specific vial label and apply the formula (units = mg / mg/mL x 100), the same titration logic applies across providers. The brand on the vial does not change the math.

For provider comparisons, see Mochi Health reviews, Henry Meds reviews, Ivim Health reviews, Vitastir tirzepatide review, and Calibrate weight loss reviews.